Literature DB >> 1734910

Racial differences in the frequencies of scleroderma-related autoantibodies.

J D Reveille1, E Durban, R Goldstein, R Moreda, F C Arnett.   

Abstract

OBJECTIVE: To determine demographic differences in scleroderma-related autoantibodies.
METHODS: One hundred fifty-six patients with systemic sclerosis were prospectively examined for anticentromere antibodies (ACA), anti-topoisomerase I (anti-topo I, or Scl-70), antinucleolar, and anti-U1 RNP autoantibodies.
RESULTS: ACA was found in 36% of Caucasians and 4% of American blacks (P = 0.002, odds ratio [OR] 15). Anti-topo I was found in 37% of American blacks, compared with 17% of Caucasians (P = 0.04, OR 3). No significant differences in the frequencies of antinucleolar and anti-U1 RNP autoantibodies were found.
CONCLUSION: These data suggest important demographic differences in scleroderma-associated autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1734910     DOI: 10.1002/art.1780350215

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

2.  Clinical setting of patients with systemic sclerosis by serum autoantibodies.

Authors:  U Picillo; S Migliaresi; M R Marcialis; A M Ferruzzi; G Tirri
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

Review 3.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

4.  Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Authors:  Roozbeh Sharif; Marvin J Fritzler; Maureen D Mayes; Emilio B Gonzalez; Terry A McNearney; Hilda Draeger; Murray Baron; Daniel E Furst; Dinesh K Khanna; Deborah J del Junco; Jerry A Molitor; Elena Schiopu; Kristine Phillips; James R Seibold; Richard M Silver; Robert W Simms; Marilyn Perry; Carlos Rojo; Julio Charles; Xiaodong Zhou; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Frank C Arnett
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

Review 5.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

6.  Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele.

Authors:  P G Vlachoyiannopoulos; U G Dafni; I Pakas; M Spyropoulou-Vlachou; C Stavropoulos-Giokas; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

7.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 8.  Racial differences between blacks and whites with systemic sclerosis.

Authors:  Richard M Silver; Galina Bogatkevich; Elena Tourkina; Paul J Nietert; Stanley Hoffman
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

9.  A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis.

Authors:  Virginia Steen; Robyn T Domsic; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2012-09

Review 10.  Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations.

Authors:  John D Reveille
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.